
Cellectis SA
Prices are adjusted according to historical splits.

Vitals
- Today's Low:
- $1.8
- Today's High:
- $1.89
- Open Price:
- $1.8
- 52W Low:
- $1.8
- 52W High:
- $5.04
- Prev. Close:
- $1.86
- Volume:
- 74500
Company Statistics
- Market Cap.:
- $112.04 million
- Book Value:
- 2.584
- Revenue TTM:
- $25.72 million
- Operating Margin TTM:
- -348.57%
- Gross Profit TTM:
- $23.95 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -17.42%
- Return on Equity TTM:
- -54.46%
Company Profile
Cellectis SA had its IPO on 2007-02-07 under the ticker symbol CLLS.
The company operates in the Healthcare sector and Biotechnology industry. Cellectis SA has a staff strength of 0 employees.
Stock update
Shares of Cellectis SA opened at $1.8 at the start of the last trading session i.e. 2023-03-19.
The stocks traded within a range of $1.8 - $1.89, and closed at $1.88.
This is a +1.08% increase from the previous day's closing price.
A total volume of 74,500 shares were traded at the close of the day’s session.
In the last one week, shares of Cellectis SA have slipped by -9.4%.
Cellectis SA's Key Ratios
Cellectis SA has a market cap of $112.04 million, indicating a price to book ratio of 0.7503 and a price to sales ratio of 4.4785.
In the last 12-months Cellectis SA’s revenue was $25.72 million with a gross profit of $23.95 million and an EBITDA of $-78507336. The EBITDA ratio measures Cellectis SA's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Cellectis SA’s operating margin was -348.57% while its return on assets stood at -17.42% with a return of equity of -54.46%.
In Q3, Cellectis SA’s quarterly earnings growth was a positive 0% while revenue growth was a positive 26.8%.
Cellectis SA’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-1.89 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Cellectis SA’s profitability.
Cellectis SA stock is trading at a EV to sales ratio of 5.0715 and a EV to EBITDA ratio of -0.6403. Its price to sales ratio in the trailing 12-months stood at 4.4785.
Cellectis SA stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $279.58 million
- Total Liabilities
- $53.03 million
- Operating Cash Flow
- $-61000.00
- Capital Expenditure
- $622000
- Dividend Payout Ratio
- 0%
Cellectis SA ended 2023 with $279.58 million in total assets and $0 in total liabilities. Its intangible assets were valued at $279.58 million while shareholder equity stood at $136.64 million.
Cellectis SA ended 2023 with $0 in deferred long-term liabilities, $53.03 million in other current liabilities, 2949000.00 in common stock, $-409921000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $119.01 million and cash and short-term investments were $119.01 million. The company’s total short-term debt was $18,350,000 while long-term debt stood at $14.70 million.
Cellectis SA’s total current assets stands at $140.27 million while long-term investments were $8.93 million and short-term investments were $0. Its net receivables were $12.95 million compared to accounts payable of $22.35 million and inventory worth $0.
In 2023, Cellectis SA's operating cash flow was $-61000.00 while its capital expenditure stood at $622000.
Comparatively, Cellectis SA paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $1.88
- 52-Week High
- $5.04
- 52-Week Low
- $1.8
- Analyst Target Price
- $10.1
Cellectis SA stock is currently trading at $1.88 per share. It touched a 52-week high of $5.04 and a 52-week low of $5.04. Analysts tracking the stock have a 12-month average target price of $10.1.
Its 50-day moving average was $2.61 and 200-day moving average was $2.67 The short ratio stood at 1.92 indicating a short percent outstanding of 0%.
Around 1213% of the company’s stock are held by insiders while 1657.9% are held by institutions.
Frequently Asked Questions About Cellectis SA
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20×22 for relapsed or refractory B-Cell NHL. The company has strategic alliances with Allogene Therapeutics, Inc. and Les Laboratoires Servier; research collaboration and exclusive license agreement with Iovance Biotherapeutics; and collaboration and license agreement with Cytovia Therapeutics. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.